A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give the protease
inhibitor (PI) amprenavir (APV) to patients with fat production and distribution problems
associated with other PIs.
Protease inhibitors are very effective in treating HIV-1 disease. However, patients who take
these drugs often have problems, such as hyperlipidemia (an increased level of fat in the
blood) and lipodystrophy (problems with the way fat is produced and distributed in the body).
Doctors do not know exactly how PIs are related to these problems. APV has been shown to be
safe and effective in lowering plasma viral loads (level of HIV in the blood). APV may be
useful for patients who develop complications associated with other PIs.
Phase:
N/A
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Amprenavir HIV Protease Inhibitors Protease Inhibitors